Nicorette Mini Return Provides More Retail Therapy For Glaxo Consumer
This article was originally published in The Tan Sheet
Following the February launch of its Flonase Allergy Relief OTC switch and the return of alli following a recall, Glaxo adds another momentum driver before the pending launch of its consumer product JV with Novartis by returning Nicorette minis as an OTC revenue source.
You may also be interested in...
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.